SmithKline Beecham
This article was originally published in The Tan Sheet
Executive Summary
Sells A-200 lice treatment product line to Hogil Pharmaceutical, a privately held consumer and pet health care products firm based in Armonk, N.Y. SmithKline did not disclose terms of the deal, which is effective Dec. 31. SmithKline explained in a Dec. 30 press release that its decision to divest A-200, which is marketed in the U.S. and Puerto Rico, is part of the company's strategy to concentrate on its "core OTC brands." Hogil will receive "transitional services" from SmithKline for "up to one year," the release states
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC